Skip to main
MNMD

MNMD Stock Forecast & Price Target

MNMD Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Mind Medicine Inc. is advancing its late-stage clinical pipeline with promising results for its lead product candidates, MM120 and MM402, which are targeting significant mental health disorders such as generalized anxiety disorder, clinical depressive disorder, and autism spectrum disorder. The Phase 2b data highlight that MM120 has achieved statistically significant improvements in both the Montgomery-Asberg Depression Rating Scale (MADRS) and the Hamilton Anxiety Rating Scale (HAM-A), indicating a compelling efficacy that surpasses current standard-of-care treatments. Furthermore, with both Phase 3 studies expected to read out in 2026, the company is positioned to capitalize on the increasing adoption and market potential of psychedelic therapies, offering a favorable outlook for its stock.

Bears say

Mind Medicine Inc. faces significant clinical and regulatory risks that could hinder the approval of its product candidates, specifically MM120 and MM402, impacting its financial viability and market potential. Additionally, the company is at a potential disadvantage if key patents are not secured or become contested, which may lead to insufficient protection for its assets and subsequently result in downward revisions of its valuation. Furthermore, conservative management assumptions regarding patient treatment frequency compared to earlier studies may indicate a lack of confidence in the effectiveness and market competitiveness of its therapies.

MNMD has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mind Medicine MindMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mind Medicine MindMed (MNMD) Forecast

Analysts have given MNMD a Strong Buy based on their latest research and market trends.

According to 9 analysts, MNMD has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mind Medicine MindMed (MNMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.